Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29750606 | 1.00 | TTR (0.64) | TTRALDH1A1MAPTMAPK1TDP1 | |
| SCHEMBL8867665 | 0.87 | SMN1; SMN2 (0.52) | TTRALDH1A1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL30875697 | 0.87 | SMN1; SMN2 (0.52) | TTRALDH1A1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL1667910 | 0.87 | TTR (0.68) | TTRALDH1A1MAPTMAPK1TDP1 | |
| SCHEMBL1531355 | 0.85 | ALDH1A1 (0.53) | TTRALDH1A1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL18138414 | 0.85 | ALDH1A1 (0.53) | TTRALDH1A1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL16955161 | 0.84 | MAPT (0.55) | TTRALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL520466 | 0.83 | ALDH1A1 (0.51) | TTRALDH1A1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL14136128 | 0.83 | ALDH1A1 (0.51) | TTRALDH1A1MAPTTDP1SMN1; SMN2 | |
| SCHEMBL520427 | 0.83 | ALDH1A1 (0.51) | TTRALDH1A1MAPTTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6509393-B2 | Phase change inks | XEROX CORPORATION | 2003-01-21 | — | — | US | claimed |
| US-20020137816-A1 | Phase change inks | XEROX CORPORATION | 2002-09-26 | — | — | US | claimed |
| EP-4727652-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4646402-A1 | GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2025-11-12 | — | — | EP | disclosed |
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | Kynan Duke IP, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2024256827-A1 | (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 | ThirtyFiveBio Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024147009-A1 | GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2024-07-11 | — | — | WO | disclosed |
| US-20230391775-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-4238975-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Suzhou Yabao Pharmaceutical R&D Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| WO-1999022726-A1 | N,N'-BIS(SULFONYL)HYDRAZINES USEFUL AS ANTINEOPLASTIC AGENTS | YALE UNIVERSITY (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0894084-A1 | CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5852210-A | Cinnamic acid derivatives | G. D. SEARLE & CO. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0861243-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| WO-1997036860-A1 | CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391775-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | LRRK2, COMT, PARK7 | TTR 2977/4885ALDH1A1 1791/4885MAPT 10/4885 |
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | CYP8B1, HSD11B1, HSD11B2 | TTR 2074/4885ALDH1A1 288/4885MAPT 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.